Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Buller

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
British Journal of Sports Medicine|January 13, 2022
Gait instability and estimated core temperature predict exertional heat strokeMark Buller, Rebecca Fellin, Max Bursey, et al.
BMC Genomics|July 9, 2009
Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapyAndrea Worschech, Nanhai Chen, Yong A Yu, et al.
Antiviral Research|November 14, 2017
Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric miceKelly R Long, Elena Lomonosova, Qilan Li, et al.
BMC Pharmacology & Toxicology|December 6, 2018
Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agentsHari Krishna Ananthula, Scott Parker, Erin Touchette, et al.
Vaccine|January 25, 2006
Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challengeCyril Empig, Julie R Kenner, Marcel Perret-Gentil, et al.
Plos Pathogens|March 31, 2015
Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunityRuth J Napier, Brian A Norris, Alyson Swimm, et al.
Nature|November 19, 2010
2'-O methylation of the viral mRNA cap evades host restriction by IFIT family membersStephane Daffis, Kristy J Szretter, Jill Schriewer, et al.
Journal of Virology|September 29, 2005
An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus ChallengeGuang Yang, Daniel C Pevear, Marc H Davies, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
British Journal of Sports Medicine|January 13, 2022
Gait instability and estimated core temperature predict exertional heat strokeMark Buller, Rebecca Fellin, Max Bursey, et al.
BMC Genomics|July 9, 2009
Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapyAndrea Worschech, Nanhai Chen, Yong A Yu, et al.
Antiviral Research|November 14, 2017
Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric miceKelly R Long, Elena Lomonosova, Qilan Li, et al.
BMC Pharmacology & Toxicology|December 6, 2018
Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agentsHari Krishna Ananthula, Scott Parker, Erin Touchette, et al.
Vaccine|January 25, 2006
Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challengeCyril Empig, Julie R Kenner, Marcel Perret-Gentil, et al.
Plos Pathogens|March 31, 2015
Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunityRuth J Napier, Brian A Norris, Alyson Swimm, et al.
Nature|November 19, 2010
2'-O methylation of the viral mRNA cap evades host restriction by IFIT family membersStephane Daffis, Kristy J Szretter, Jill Schriewer, et al.
Journal of Virology|September 29, 2005
An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus ChallengeGuang Yang, Daniel C Pevear, Marc H Davies, et al.
Pageof 6